is dedicated to treating rare and severe genetic
bone-growth disorders for which there are currently
no approved drug therapy.
Enobia focuses on the development of therapeutics
for the treatment of severe orphan disorders affecting
the bone, where no approved therapy exits. These
disorders result from a well characterized imbalance
in specific enzymes resulting in impaired bone